Core Viewpoint - Quantum BioPharma Ltd. has partnered with BitGo Trust Company to manage and store its cryptocurrency assets, including Bitcoin, Solana, XRP, and DOGE coin, enhancing its security and compliance as a public company [1][2]. Company Overview - Quantum BioPharma is a biopharmaceutical company focused on developing innovative assets and biotech solutions for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders [3]. - The company is advancing its lead compound, Lucid-MS, which is designed to prevent and reverse myelin degradation associated with multiple sclerosis [3]. - Quantum BioPharma retains a 22.95% ownership stake in Celly Nutrition Corp., which markets the product unbuzzd™, and is entitled to a 7% royalty on sales until total payments reach $250 million, after which the royalty will decrease to 3% [3]. Partnership with BitGo - BitGo will provide institutional-grade custody services, including multi-signature wallets and 100% cold storage technology, to protect Quantum's cryptocurrency assets from theft and unauthorized access [2]. - The partnership aligns with Quantum's priorities for security and compliance as it expands its engagement with cryptocurrency assets [2][3]. Industry Context - The collaboration with BitGo reflects a broader trend where institutions like Quantum are shaping the future of digital finance, emphasizing the need for secure and compliant infrastructure [3][5]. - BitGo is recognized as a leading provider of digital asset solutions, serving thousands of institutions and handling a significant portion of Bitcoin network transactions [5].

Core Insights - Quantum BioPharma Ltd. has signed an agreement with a global pharmaceutical contract research organization to prepare an IND application package for Lucid-21-302 (Lucid-MS) with the US FDA, aiming to initiate a Phase 2 trial for multiple sclerosis (MS) [1][3] - Lucid-21-302 is a first-in-class, non-immunomodulatory, neuroprotective compound designed to prevent demyelination, a key factor in MS and other neurodegenerative diseases [2] - The company plans to submit the IND application to the FDA in Q4 2025, marking a significant step towards advancing its treatment for MS [3] Company Overview - Quantum BioPharma is focused on developing innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders, with a lead compound, Lucid-MS, that has shown potential in preclinical models [4] - The company retains a 20.11% ownership stake in Celly Nutrition Corp., which is involved in the marketing of unbuzzd™, and has established a royalty agreement that includes 7% of sales until reaching $250 million, after which the royalty will drop to 3% [4] - Quantum BioPharma also maintains a portfolio of strategic investments through its subsidiary, FSD Strategic Investments Inc., which includes loans secured by residential or commercial property [4]

Core Viewpoint - Quantum BioPharma Ltd. has strategically increased its investment in Bitcoin and other cryptocurrencies, reflecting confidence in their potential for returns and as a hedge against the Canadian dollar [1][2]. Group 1: Cryptocurrency Investment - The company has purchased an additional USD $1,000,000 worth of Bitcoin and other cryptocurrencies, bringing the total investment to USD $4,500,000 [1]. - Quantum BioPharma plans to continue allowing financing and transactions in cryptocurrencies, indicating a commitment to integrating digital assets into its operations [2]. Group 2: Compliance and Custodianship - All cryptocurrency holdings are managed by a fully compliant custodian, ensuring adherence to financial and audit regulations [3]. - The company will actively monitor market conditions to adjust its cryptocurrency holdings as deemed appropriate [3]. Group 3: Company Overview - Quantum BioPharma is focused on developing innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders, with a lead compound, Lucid-MS, aimed at treating multiple sclerosis [4]. - The company retains a 20.11% ownership stake in Celly Nutrition, which includes a royalty agreement for sales from its product unbuzzd™ [4].

Core Viewpoint - Quantum BioPharma Ltd. is actively participating in two upcoming conferences to engage with institutional investors and showcase its innovative biopharmaceutical solutions [1][2]. Company Overview - Quantum BioPharma is a biopharmaceutical company focused on developing innovative assets and biotech solutions for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders [4]. - The company is advancing its lead compound, Lucid-MS, which is designed to prevent and reverse myelin degradation associated with multiple sclerosis, currently in preclinical development [4]. - Quantum BioPharma retains a 22.95% ownership stake in Celly Nutrition Corp., which markets the unbuzzd™ product, and is entitled to a 7% royalty on sales until total payments reach $250 million, after which the royalty rate will decrease to 3% [4]. Conference Participation - Jason Sawyer, the Head of Finance and M&A, will represent Quantum BioPharma at the Sidoti Micro-Cap Conference on May 21, 2025, and the A.G.P. Virtual Healthcare Conference on May 22, 2025 [2][3]. - At the Sidoti Micro-Cap Conference, Sawyer will host one-on-one meetings with institutional investors and deliver a webcast presentation [2][3].

Core Viewpoint - Quantum BioPharma Ltd. has completed dosing in 90-day oral toxicity and toxicokinetic studies for its drug Lucid-21-302, aimed at treating Multiple Sclerosis, which is a significant step towards submitting an IND application to the US FDA [1][2]. Company Overview - Quantum BioPharma is a biopharmaceutical company focused on developing innovative assets and biotech solutions for neurodegenerative and metabolic disorders, including Multiple Sclerosis [3]. - The company is advancing its lead compound, Lucid-MS, which is a patented new chemical entity designed to prevent and reverse myelin degradation, a key mechanism in Multiple Sclerosis [3]. Development Progress - The completion of toxicity studies for Lucid-21-302 brings the company closer to initiating a Phase 2 trial for Multiple Sclerosis [2]. - The company plans to submit the IND application for Lucid-21-302 before the end of the year [2]. Strategic Investments - Quantum BioPharma retains a 22.95% ownership stake in Celly Nutrition, which is involved in the OTC version of its product unbuzzd™. The agreement includes a 7% royalty on sales until total payments reach $250 million, after which the royalty will drop to 3% [3]. - The company maintains a portfolio of strategic investments through its subsidiary, FSD Strategic Investments Inc., which includes loans secured by residential or commercial property [3].

Company Overview - Quantum BioPharma Ltd. is hosting a Business Update Conference Call on May 6, 2025, at 04:30 PM ET, led by its Founder and CEO, Zeeshan Saeed, and Head of Finance and M&A, Jason Sawyer [1][5]. Forward-Looking Statements - The conference call may include forward-looking statements that represent the company's current judgment on future events, which are subject to risks and uncertainties that could lead to actual results differing materially [2][4]. - Participants are cautioned not to place undue reliance on these forward-looking statements, as they reflect opinions only as of the date of the presentation [3].

Core Viewpoint - Quantum BioPharma Ltd. has filed an amended complaint alleging market manipulation by several banks, seeking damages exceeding $700 million USD due to the alleged manipulation of its stock price through "spoofing" techniques from January 2020 to August 2024 [1][2][3]. Group 1: Legal Proceedings - The amended complaint was filed on May 1, 2025, in response to a Motion to Dismiss from the banks [1]. - The lawsuit claims that CIBC World Markets and RBC Dominion Securities, among others, violated the Securities Exchange Act of 1934 [1][2]. - The law firms Christian Attar and Freedman Normand Friedland LLP are representing the company on a contingency basis, alleviating financial pressure for legal costs [2]. Group 2: Allegations of Market Manipulation - The complaint alleges that the defendants engaged in "spoofing" techniques that artificially depressed Quantum BioPharma's stock price [2]. - The company asserts that the stock was trading over $460 USD per share in January 2020, with a market capitalization nearing $1 billion USD [3]. - Quantum BioPharma believes that additional banks and brokers may also be involved in the alleged manipulation but will not disclose their names until more evidence is gathered [3]. Group 3: Company Overview - Quantum BioPharma is focused on developing innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders [7]. - The company is advancing its lead compound, Lucid-MS, which aims to prevent and reverse myelin degradation associated with multiple sclerosis [8]. - Quantum BioPharma retains a 22.95% ownership stake in Celly Nutrition Corp., which includes a royalty agreement on sales from its product unbuzzd™ [8].

Core Viewpoint - Quantum BioPharma Ltd. is set to host a Business Update Conference Call on May 6, 2025, to discuss its year-end financial results, regulatory initiatives, commercial-readiness activities, and anticipated milestones [1][2]. Group 1: Conference Call Details - The conference call will be led by CEO Zeeshan Saeed and Head of Finance and M&A Jason Sawyer, followed by a Q&A session [2]. - The call is scheduled for May 6, 2025, at 4:30 p.m. Eastern time, with dial-in and webcast access provided [2]. - A telephone replay will be available approximately three hours after the call and will run until August 6, 2025 [2]. Group 2: Company Overview - Quantum BioPharma is focused on developing innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders [3]. - The company’s lead compound, Lucid-MS, is designed to prevent and reverse myelin degradation associated with multiple sclerosis, showing promise in preclinical models [3]. - Quantum BioPharma retains a 25.71% ownership stake in Celly Nutrition, which markets the unbuzzd™ product, and is entitled to a 7% royalty on sales until reaching $250 million, after which the royalty will decrease to 3% [3].

Core Viewpoint - Quantum BioPharma Ltd. has appointed Kevin Malone as an advisor to the Board of Directors, leveraging his extensive experience in wealth management and stock trading, particularly in combating market manipulation [1][5]. Company Overview - Quantum BioPharma is a biopharmaceutical company focused on developing innovative treatments for neurodegenerative and metabolic disorders, including multiple sclerosis (MS) [7]. - The company is advancing its lead compound, Lucid-MS, which is designed to prevent and reverse myelin degradation, a key factor in MS, and is currently in preclinical development [7]. - Quantum BioPharma retains a 25.71% ownership stake in Celly Nutrition Corp., which markets the product unbuzzd™, and is entitled to a 7% royalty on sales until total payments reach $250 million, after which the royalty rate will drop to 3% [7]. Kevin Malone's Background - Kevin Malone has over 40 years of experience in wealth management and launched Malone Wealth in 2021, focusing on pattern recognition and data research [2]. - His investment philosophy emphasizes rigorous research, disciplined risk management, and a long-term approach to maximize returns while minimizing risk [3]. - Malone is committed to fighting market corruption and has initiated a charitable fund aimed at improving financial literacy in the U.S. public education system [4]. Strategic Importance of Malone's Appointment - The CEO of Quantum BioPharma, Zeeshan Saeed, expressed enthusiasm about Malone's expertise, particularly in naked short squeeze strategies, which will enhance the company's efforts against market manipulation [5]. - Malone's personal experiences with market corruption, including the GameStop incident in 2021, have motivated him to become a fiduciary dedicated to combating such practices [6].

Core Viewpoint - Quantum BioPharma Ltd. has successfully dismissed a reconsideration motion by Dr. Raza Bokhari, affirming the company's position in a legal dispute regarding his termination as CEO [1][2]. Legal Proceedings - Dr. Raza Bokhari's claim of wrongful dismissal was dismissed by Arbitrator Cunningham, resulting in Quantum BioPharma being awarded approximately CAD $2.81 million in arbitration costs plus interest [2]. - The Court of Appeal awarded an additional CAD $180,000 in costs related to Dr. Bokhari's failed motion for leave to appeal [2]. - Quantum BioPharma has initiated a Petition to Confirm Arbitration Award in the U.S. District Court to collect the awarded amounts from Dr. Bokhari, which includes various monetary judgments totaling USD $147,301.04 and CAD $2,814,229.15, among others [3]. Company Overview - Quantum BioPharma is focused on developing innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders [4]. - The company is advancing its lead compound, Lucid-MS, which aims to prevent and reverse myelin degradation associated with multiple sclerosis [4]. - Quantum BioPharma retains a 25.71% ownership stake in Celly Nutrition Corp., which markets the product UNBUZZD™, and is entitled to a 7% royalty on sales until reaching CAD $250 million, after which the royalty rate will decrease to 3% [4].